Lyon, France – June 15, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 2a clinical trial (NCT05734040) evaluating broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs).
At the internationally-renowned 2023 World Vaccine Congress, the company presented initial data from its Phase 2a trial (NCT05284799) evaluating OVX836 in combination with a Quadrivalent Influenza Vaccine (QIV) in 180 healthy volunteers. The combination demonstrated a good safety profile and no interference on the antibody immune responses driven by the QIV was observed.
Based on these encouraging data, Osivax will continue investigating the potential of OVX836 in concomitant administration with various QIVs in different age-groups by conducting this larger Phase 2a trial that is expected to enroll over 500 participants ages 18-60 across several clinical sites in Australia. To know more
